Translate this page to:
Russian
In JoVE (2)
- Гетеротопическая и Ортотопическая трахеи трансплантации в мышах используются в качестве моделей для изучения развития Облитерирующий заболевание дыхательных путей
- Человека внутренней грудной артерии (IMA) трансплантации и стентирование: модель человека для изучения развития в-стент рестеноз
Other Publications (3)
Automatic Translation
This translation into Russian was automatically generated.
English Version | Other Languages
Articles by Xiaoqin Hua in JoVE
JoVE General
Гетеротопическая и Ортотопическая трахеи трансплантации в мышах используются в качестве моделей для изучения развития Облитерирующий заболевание дыхательных путей
1Transplant and Stem Cell Immunobiology Lab (TSI), University Heart Center Hamburg, 2CVRC, University Hospital Hamburg, 3Department of CT Surgery, Stanford University School of Medicine
Это видео показывает и сравнивает два экспериментальных моделей для изучения развития облитерирующего заболевания дыхательных путей (ООО) у мышей, и гетеротопической ортотопической трахеи модель трансплантации.
JoVE Clinical and Translational Medicine
Человека внутренней грудной артерии (IMA) трансплантации и стентирование: модель человека для изучения развития в-стент рестеноз
1University Heart Center Hamburg, TSI-Lab, Germany, 2Cardiovascular Research Center, University of Hamburg, 3Department of Medicine, Cardiology Division, Pulmonary Hypertension Program, University of Alberta, 4Department of Medicine, Stanford University School of Medicine, 5Department of Biomedical Sciences, Institute of Physiology, Pathophysiology, and Biophysics, University of Veterinary Medicine, Vienna, 6Translumina GmbH, Hechingen, 7Department of Cardiothoracic Surgery, Stanford University School of Medicine
Это видео показывает модель для изучения развития гиперплазии интимы после установки стента использование человеческих судна (IMA) в иммунодефицитных модель крысы.
Other articles by Xiaoqin Hua on PubMed
Sustained Inhibition of Epsilon Protein Kinase C Inhibits Vascular Restenosis After Balloon Injury and Stenting
ε protein kinase C (εPKC) is involved in vascular smooth muscle cell (VSMC) activation, but little is known about its function in vascular pathology. We aimed at assessing the role of εPKC in the development of restenosis.
Immunobiology of Naïve and Genetically Modified HLA-class-I-knockdown Human Embryonic Stem Cells
Human embryonic stem cells (hESCs) can serve as a universal cell source for emerging cell or tissue replacement strategies, but immune rejection of hESC derivatives remains an unsolved problem. Here, we sought to describe the mechanisms of rejection for naïve hESCs and upon HLA class I (HLA I) knockdown (hESC(KD)). hESCs were HLA I-positive but negative for HLA II and co-stimulatory molecules. Transplantation of naïve hESC into immunocompetent Balb/c mice induced substantial T helper cell 1 and 2 (Th1 and Th2) responses with rapid cell death, but hESCs survived in immunodeficient SCID-beige recipients. Histology revealed mainly macrophages and T cells, but only scattered natural killer (NK) cells. A surge of hESC-specific antibodies against hESC class I, but not class II antigens, was observed. Using HLA I RNA interference and intrabody technology, HLA I surface expression of hESC(KD) was 88%-99% reduced. T cell activation after hESC(KD) transplantation into Balb/c was significantly diminished, antibody production was substantially alleviated, the levels of graft-infiltrating immune cells were reduced and the survival of hESC(KD) was prolonged. Because of their very low expression of stimulatory NK ligands, NK-susceptibility of naïve hESCs and hESC(KD) was negligible. Thus, HLA I recognition by T cells seems to be the primary mechanism of hESC recognition, and T cells, macrophages and hESC-specific antibodies participate in hESC killing.
Human Leukocyte Antigen I Knockdown Human Embryonic Stem Cells Induce Host Ignorance and Achieve Prolonged Xenogeneic Survival
Although human embryonic stem cells (hESC) have enormous potential for cell replacement therapy of heart failure, immune rejection of hESC derivatives inevitably would occur after transplantation. We therefore aimed to generate a hypoantigeneic hESC line with improved survival characteristics.
